Corcept Q3 Revenue Jumps 64.0% to $340.5 Million on Lifyorli Launch; Reiterates 2026 Guidance
Corcept Therapeutics said third-quarter revenue jumped 64.0% to $340.5 million as its new ovarian cancer drug Lifyorli added $91.4 million in sales, and it reiterated its 2026 revenue guidance of $1.1 billion to $1.2 billion.
Net income rose to $126.8 million, or $1.01 per diluted share, from $19.7 million, or $0.16, a year earlier, according to the earnings release the Redwood City, California, company furnished with an 8-K on Tuesday.
Sales of Korlym and its authorized generic, the core of its endocrinology business, rose 20.0% from a year earlier to $249.1 million. Lifyorli revenue grew 92.2% from the second quarter.
"Lifyorli's uptake in ovarian cancer has been both very rapid and broad," CEO Joseph K. Belanoff said in the release. "Since its April 1st launch, more than 2,300 patients have received the medication. More than 1,700 physicians have prescribed it."
Profit and cash
Operating expenses were $225.7 million, up from $197.4 million a year earlier, as selling, general and administrative costs climbed to $164.4 million from $124.0 million. Research and development spending fell to $56.7 million from $68.8 million.
Cash and investments rose by $117.7 million during the quarter to $662.3 million at Sept. 30. That balance reflects $43.7 million of stock bought back under the company's repurchase program in the third quarter, Corcept said.
Regulatory calendar
The Food and Drug Administration has set a Prescription Drug User Fee Act date of Dec. 17, 2026, for Corcept's resubmitted application for relacorilant in patients with Cushing's syndrome. The company also expects European approval of relacorilant plus nab-paclitaxel for platinum-resistant ovarian cancer by the end of this year.
Corcept highlighted a consensus report from the American Diabetes Association and the European Association for the Study of Diabetes, published in October, that recommends screening for hypercortisolism in diabetic patients with poor glucose control despite ongoing medications and cites mifepristone as a potentially beneficial treatment.
Pipeline readouts
In the Phase 2 BELLA Part A trial of 95 patients with platinum-resistant ovarian cancer, relacorilant plus nab-paclitaxel and bevacizumab produced median progression-free survival of 7.2 months and an objective response rate of 59%. Results were strongest among patients who had not previously received bevacizumab, with median progression-free survival of 8.1 months.
In amyotrophic lateral sclerosis, exploratory analyses of the DAZALS study showed patients on dazucorilant 300 mg had an 84% lower risk of death in the study's first year than those on placebo. Corcept plans to begin a Phase 3 trial next year. Data from its BELLA Part B and Part C, TRIDENT and SYNERGY trials are expected by the end of next year.
By the numbers
- Revenue: $340.5 million, up 64.0%
- Diluted EPS: $1.01, versus $0.16
- Korlym and authorized generic: $249.1 million, up 20.0%
- Lifyorli: $91.4 million
- Cash and investments: $662.3 million
- 2026 revenue guidance: $1.1 billion to $1.2 billion, reiterated
Sources
- Corcept Therapeutics Form 8-K with third-quarter 2026 earnings release, filed Nov. 3, 2026 (accession 0001628280-26-069494)
This article is for informational and educational purposes only and is not investment advice. It is not a recommendation to buy or sell any security.
Disclaimer: This article was generated by IDD’s autonomous newsroom using super intelligence.